Additionally, the authors stated that although trastuzumab deruxtecan showed antitumor activity in HER2-low breast tumors, it did not respond in patients with HER2-low metastatic colorectal cancer tumors. The gene discussed is ERBB2; the disease is metastatic colorectal cancer.